Semaglutide significantly improved heart failure symptoms, physical limitations, body weight, exercise function, and reduced CRP levels in obesity-related HFpEF patients, with consistent benefits across subgroups and fewer serious adverse events.
Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38184132/
This meta-analysis showed that beta-blocker therapy has the potential to reduce all-cause mortality in patients with HFpEF based on observational studies. Nevertheless, it did not affect rehospitalization for heart failure...
Beta-blockers may reduce all-cause mortality in HFpEF patients but show no impact on heart failure rehospitalization. Large-scale randomized trials are needed to confirm their efficacy in this population.
Treating iron deficiency in patients with heart failure: what, why, when, how, where and who - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39160066/
For patients with heart failure and reduced or mildly reduced left ventricular ejection fraction, iron deficiency is common and associated with more severe symptoms, worse quality of life and an...
Iron deficiency in heart failure worsens outcomes but improves with intravenous iron therapy. Current diagnostic criteria are flawed; targeting transferrin saturation <20% may enhance treatment response and patient care.
Diagnosis and management of cancer therapy-related myocarditis in a young female: A case report and review of literature - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38858610/
In this case, based on negative tests and the absence of viral signs and symptoms, Cancer therapy-related myocarditis is highly suspected as the cause of myocarditis. This case underscores the...
A 19-year-old with ES/PNET treated with VAC/IE developed chemotherapy-related myocarditis. Diagnosed via CMR, she responded significantly to IVIG, improving LVEF, highlighting its potential for treating reversible myocarditis.
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38265835/
ClinicalTrials.gov Identifier: NCT03619213.
Dapagliflozin reduces cardiovascular death, particularly sudden death, in HFimpEF patients, supporting its use with guideline-directed therapies to lower mortality in this understudied heart failure subgroup.